

Paper alert

393 Peter Norman, David P Rotella & James Melville

Patent alert

404 Susan Wan

Web alert

417 David Cavalla

The Chemistry of Drug Design and Lead Optimization

Edited by William Greenlee & Manoj Desai

419 William J Greenlee & Manoj C Desai

Editorial overview: The role of medicinal chemists in drug discovery

421 Celia Dominguez, David A Powers & Nuria Tamayo

p38 MAP kinase inhibitors: Many are made, but few are chosen

431 David M Duhl & Paul A Renhowe

Inhibitors of kinesin motor proteins - research and clinical progress

437 Brad R Henke & Dennis Heyer

Recent advances in estrogen receptor modulators

449 William D Shipe, Scott E Wolkenberg, David L Williams Jr & Craig W Lindsley

Recent advances in positive allosteric modulators of metabotropic glutamate receptors

458 Chi B Vu

Recent advances in the design and optimization of adenosine A_{2A} receptor antagonists

469 Michael B Gravestock

Recent developments in the discovery of novel oxazolidinone antibacterials

478 Devanesan Loganathan & Harry Morrison

'Photocisplatin' reagents

487 Bruce A Posner

High-throughput screening-driven lead discovery: Meeting the challenges of finding new therapeutics

495 Li Di & Edward H Kerns

Application of pharmaceutical profiling assays for optimization of drug-like properties

505 Xingrong Liu & Cuiping Chen

Strategies to optimize brain penetration in drug discovery

513 Tomas Lundqvist

The devil is still in the details - driving early drug discovery forward with biophysical experimental methods